Dr Zenator Agyemang Rawlings, the Member of Parliament (MP) for Korle Klottey, has expressed commitment to leading a strong advocacy in getting the Lupus disease captured under the National Health ...

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Five months after his father passed, Kenny Lewis keeps his dad's memory with him on the same baseball field his father worked on as the groundskeeper.

Angelys Balek reveals the vision behind her brand – where sustainability, craftsmanship, and a pursuit of innovation come ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune ...

When healthcare providers dismiss symptoms, it can cause lasting harm. A new study reveals how such invalidation affects ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and ...

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

This woman in her early 30s with an 11 year history of systemic lupus erythematosus (SLE) experienced a sudden disease ...